Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) used short-term to treat moderate to severe pain, often after surgery. It reduces pain and inflammation by blocking prostaglandin synthesis. It is available oral, injectable (IV/IM), and topical/ocular forms. Systemic use is generally limited to short courses because of safety risks.

Xanax is the brand name for alprazolam, a benzodiazepine used to treat anxiety disorders and panic disorder. It works on GABA receptors in the brain to produce a calming effect. It’s prescribed for short- to medium-term management of anxiety and panic symptoms.

Ketorolac given IV or IM can start to relieve pain within 10–30 minutes; oral ketorolac typically takes 30–60 minutes. Xanax is fast-acting for anxiety: oral immediate-release tablets often begin to reduce symptoms within 15–60 minutes.

Ketorolac’s analgesic effect generally lasts 4–6 hours per dose; duration depends on route and dose. Xanax immediate-release effects typically last 4–6 hours; extended-release formulations provide longer coverage. Individual metabolism and dosing affect duration.

Common ketorolac side effects include stomach pain, dyspepsia, nausea, headache, dizziness, fluid retention, and injection-site pain (if parenteral). More serious risks include gastrointestinal bleeding, kidney impairment, and increased cardiovascular events with prolonged use.

Common side effects of Xanax include drowsiness, dizziness, impaired coordination, memory problems, and slowed reaction times. Long-term or high-dose use can lead to tolerance, dependence, and significant withdrawal symptoms when stopped abruptly.

People with active peptic ulcer disease, known bleeding disorders, severe renal impairment, recent or upcoming major surgery with bleeding risk, or known hypersensitivity to NSAIDs should avoid ketorolac. It’s contraindicated in patients at high risk of bleeding and in the third trimester of pregnancy.

Xanax should be avoided in patients with acute narrow-angle glaucoma, severe respiratory insufficiency, sleep apnea, or known hypersensitivity to benzodiazepines. It should be used very cautiously in people with substance use disorders, and avoided or used with caution during pregnancy and breastfeeding.

Serious risks include gastrointestinal bleeding and perforation, kidney injury, increased cardiovascular risk (especially with long-term NSAID use), and potential for severe allergic reactions. Systemic ketorolac should not be used for more than 5 days in adults due to increased risk.

Serious risks include respiratory depression (especially when combined with opioids or alcohol), profound sedation, cognitive impairment, dependence and withdrawal (which can be severe or life-threatening), and increased risk of accidents. Co-prescribing with opioids carries a boxed warning due to additive effects.

There is no direct pharmacologic interaction that is universally dangerous between ketorolac and Xanax; however, combining medications should always be done under prescriber guidance. Be cautious if either drug is used with other CNS depressants, anticoagulants, or agents that increase bleeding risk.

Ketorolac is cleared in part by the kidneys and can worsen renal function; it should be avoided or dose-adjusted in renal impairment. Xanax is metabolized by the liver (CYP3A); liver impairment can increase alprazolam levels, requiring dose adjustments or alternative therapy.

Ketorolac is generally avoided during pregnancy, especially in the third trimester (risk of premature closure of the fetal ductus arteriosus) and during breastfeeding unless a clinician advises otherwise. Xanax is generally not recommended during pregnancy because of potential fetal risk and neonatal withdrawal; breastfeeding while taking alprazolam can expose the infant to sedative effects.

For suspected overdose, seek emergency medical help immediately. Ketorolac overdose can cause severe gastrointestinal bleeding, kidney impairment, and other systemic issues. Xanax overdose can cause severe respiratory depression, sedation, and coma, especially with other CNS depressants—supportive care, airway management, and naloxone do not reverse benzodiazepines but flumazenil can be used in specific settings under close monitoring.

Yes. Alcohol increases the risk of stomach bleeding with NSAIDs and can exacerbate drowsiness, dizziness, and impairment with Xanax. Combining alcohol with Xanax is especially dangerous because the sedative and respiratory-depressant effects are additive and can be life-threatening.

Dosing varies by formulation and patient factors; ketorolac is typically prescribed for short-term use only. For systemic (oral or parenteral) therapy, most guidelines limit use to a maximum of 5 days in adults due to cumulative risk of bleeding, renal harm, and cardiovascular events. Follow your prescriber’s instructions.

Typical initial dosing for anxiety often starts low (for example 0.25–0.5 mg two to three times daily) and is adjusted based on response. Higher doses may be used for panic disorder under supervision. Because of tolerance and dependence risks, long-term use and high doses should be carefully managed by a clinician.

Ketorolac interacts with anticoagulants (increased bleeding), other NSAIDs, corticosteroids (increased GI risk), SSRIs (increased bleeding risk), and certain antihypertensives (reduced effect). Xanax interacts strongly with CYP3A inhibitors (e.g., ketoconazole, some macrolide antibiotics) which increase alprazolam levels, and with other CNS depressants (opioids, alcohol) that can cause severe sedation or respiratory depression.

Yes. Like other NSAIDs, ketorolac can trigger hypersensitivity reactions including hives, bronchospasm, and anaphylaxis, and can worsen asthma in people with aspirin-sensitive asthma. Any signs of allergic reaction require immediate medical attention.

Dependence can develop within weeks to months of regular use, especially at higher doses. Withdrawal symptoms (anxiety rebound, insomnia, tremor, seizures in severe cases) can occur when stopping abruptly. Tapering under medical supervision is recommended to minimize withdrawal.

Ketorolac increases bleeding risk and can affect renal function; many surgeons avoid systemic ketorolac in settings with significant bleeding risk or in certain perioperative periods. Always inform surgical teams if you’ve recently taken ketorolac; they’ll advise on timing and alternatives.

Do not stop abruptly. A gradual taper supervised by a clinician is recommended to reduce withdrawal risk. The taper schedule depends on dose, duration, and individual risk factors. In some cases, switching to a longer-acting benzodiazepine before tapering may be considered.

Yes. For pain, alternatives include acetaminophen, physical therapy, nerve-targeted treatments, and interventional procedures depending on cause. For anxiety, cognitive behavioral therapy, lifestyle changes, SSRIs or SNRIs, and non-benzodiazepine anxiolytics are commonly used options. Discuss options with a clinician.

Ketorolac is an NSAID that inhibits cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin production and thus inflammation and pain. Xanax (alprazolam) is a benzodiazepine that enhances GABA-A receptor activity, increasing inhibitory neurotransmission and producing anxiolytic and sedative effects.

Xanax has a significant risk of physical dependence and withdrawal with regular use. Ketorolac does not cause physiological dependence typical of benzodiazepines, but overuse can lead to medical harms like renal injury or GI bleeding—not addiction.

Ketorolac is intended for short-term acute pain management (often post-op) and is not suitable for chronic long-term pain due to safety limits. Xanax is prescribed for acute anxiety and panic but has significant concerns for long-term use (dependence); long-term anxiety is often better managed with non-benzodiazepine strategies.

Ketorolac’s major risks center on bleeding, gastrointestinal injury, and kidney effects. Xanax’s major risks center on sedation, cognitive impairment, dependence, and respiratory depression when combined with other depressants. Both can cause dizziness and impact daily functioning.

Xanax combined with opioids is particularly dangerous due to additive CNS and respiratory depression and carries a boxed warning. Ketorolac combined with opioids increases risk of GI side effects and may increase bleeding but is less likely to cause additive respiratory depression.

Older adults are more susceptible to ketorolac’s renal and gastrointestinal toxicity and should generally receive lower doses or avoid systemic ketorolac. Older adults are also more sensitive to Xanax’s sedative, cognitive, and fall risks, and usually require lower doses or alternative therapies.

Both have important interactions. Xanax has critical interactions via CYP3A metabolism (CYP3A inhibitors/inducers) and dangerous potentiation with other CNS depressants. Ketorolac’s clinically significant interactions are with anticoagulants, antiplatelet agents, and drugs that affect kidney function. The clinical concern depends on the patient’s full medication list.

Both drugs are typically avoided in pregnancy when possible: ketorolac especially in later pregnancy due to fetal cardiovascular risks, and Xanax because of potential teratogenicity and neonatal withdrawal. Both may pose risks during breastfeeding; clinicians weigh benefits versus risks.

Clinicians consider urgency, drug interactions, medical history, and risk factors. Short-term ketorolac may be used for acute postoperative pain while anxiety may be managed with non-benzodiazepine approaches or carefully limited benzodiazepine use. Combining therapies requires review of bleeding risk, respiratory depression potential (with other sedatives/opioids), and renal/hepatic function.

For ketorolac, monitoring may include renal function (serum creatinine), CBC if long-term use (bleeding risk), and signs of GI bleeding. For Xanax, monitoring focuses on clinical assessment of sedation, cognitive function, signs of misuse or withdrawal, and liver function if hepatic impairment is suspected. Regular follow-up with the prescriber is important.

For acute panic attacks, fast-acting anxiolytics like Xanax may be prescribed short-term, although non-benzodiazepine approaches are preferable for many patients. For acute postoperative pain, ketorolac is commonly used as an opioid-sparing analgesic when contraindications are absent. Each should be chosen based on the specific clinical scenario.